Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy (original) (raw)

Clinical Oncology/Epidemiology

British Journal of Cancer volume 72, pages 1259–1266 (1995)Cite this article

Abstract

Several oncogenes and tumour-suppressor genes have been identified that may have an important role in the development of human breast carcinoma. Furthermore, some of these gene alterations may be linked to the development of invasion and subsequent metastasis. Alterations in the expression of ras p21, p53 and c-erbB-2 have all been linked to tumours with rapid cellular proliferation, but the evidence that they are of prognostic importance in patients with breast cancer is conflicting. This study explores the relationship between expression of these oncoproteins and clinical outcome in 92 patients with either locally advanced or metastatic breast cancer treated with primary endocrine therapy. Specimens of the primary carcinoma were available for analysis of hormone receptor, Ki67 labelling index, epidermal growth factor receptor (EGFR), c-erbB-2, p53 and ras p21. Clinical response was measured according to UICC criteria after 6 months of treatment and all patients were followed for time to progression and overall survival. As shown previously, oestrogen receptor (ER) negativity, high Ki67 labelling index and EGFR overexpression were associated with a shorter time to progression and overall survival. However, no statistically significant relationship existed between expression of ras p21, p53 or c-erbB-2 and response to treatment, time to progression or overall survival. We conclude that staining for these three oncoproteins has no role in therapeutic decision-making in patients with advanced breast cancer. The negative finding implies that while abnormal expression of these genes may have an important role in the development of breast cancer, the variations in growth characteristics of advanced breast cancer may be influenced by other factors.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 24 print issues and online access

$259.00 per year

only $10.79 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Professional Unit of Surgery, Nottingham City Hospital, UK
    SG Archer

Authors

  1. SG Archer
    You can also search for this author inPubMed Google Scholar
  2. A Eliopoulos
    You can also search for this author inPubMed Google Scholar
  3. D Spandidos
    You can also search for this author inPubMed Google Scholar
  4. D Barnes
    You can also search for this author inPubMed Google Scholar
  5. IO Ellis
    You can also search for this author inPubMed Google Scholar
  6. RW Blamey
    You can also search for this author inPubMed Google Scholar
  7. RI Nicholson
    You can also search for this author inPubMed Google Scholar
  8. JFR Robertson
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Archer, S., Eliopoulos, A., Spandidos, D. et al. Expression of ras p21, p53 and c-_erb_B-2 in advanced breast cancer and response to first line hormonal therapy.Br J Cancer 72, 1259–1266 (1995). https://doi.org/10.1038/bjc.1995.497

Download citation